Aprea Therapeutics Inc. (APRE) is a biopharmaceutical company with an intense focus on developing and commercializing novel cancer therapies that show potential to redefine the standards of care. The firm, which was established in 2006, is located in Boston, Massachusetts and Stockholm, Sweden. It is incorporated in the state of Delaware in the United States and is publicly traded on the NASDAQ stock exchange under the ticker symbol 'APRE.'
Aprea Therapeutics Inc. primarily targets the p53 tumor suppressor protein, the gene for which is deleted or mutated in about half of all human cancers. It developed the concept of small molecules called PRIMA Met Inhibitor that targets p53 and effectively enhance its ability in restoring the cell cycle arrest and trigger cell death in cancer cells. The main research compound currently in development is EP300-initiated p53 reactivation compounds. The most advanced of these innovations is aprinocarsen (APR-246), now in clinical phase 3 trial for treatment of myelodysplastic syndromes (MDS), a group of rare blood disorders. This constitutes a paradigm shift in cancer treatment showing substantial promise, and APRE is striving to develop it for a broad range of human cancers.
Aprea Therapeutics also has a substantive drug pipeline of several promising and innovative compounds in different stages of clinical development for the treatment of various forms of cancer. These achievements highlight the company's commitment to research and development, and its drive for innovation in the field of cancer therapy.
The firm's leadership comprises a team of passionate scientists, investors, and businessmen with extensive experience in biotechnology and life sciences. They partner with world-class investors, research institutions, and scientists, with the shared goal of transforming the landscape of cancer therapy.
Despite being a relatively young company, Aprea Therapeutics Inc has shown strong growth potential and dedication to its mission. The future advancements from this company could play a pivotal role in revolutionary cancer care, which could significantly alter the prognosis of individuals with genetically defined cancers, improving both the quality and the duration of their lives. It’s clear that the success of Aprea Therapeutics could be integral to ushering new hope for cancer patients around the world.